Item 9 Labs Corp.
INLB · OTC
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.38 | -0.43 | 0.62 |
| FCF Yield | -20.41% | -6.59% | -1.67% | -5.16% |
| EV / EBITDA | -2.87 | -33.21 | -22.55 | -19.76 |
| Quality | ||||
| ROIC | -25.60% | -5.20% | -33.14% | -38.68% |
| Gross Margin | 33.61% | 39.26% | 40.58% | 48.19% |
| Cash Conversion Ratio | 0.07 | 0.55 | 0.09 | 0.24 |
| Growth | ||||
| Revenue 3-Year CAGR | 38.88% | 64.44% | 80.75% | 172.47% |
| Free Cash Flow Growth | 6.31% | -431.93% | 82.52% | -482.92% |
| Safety | ||||
| Net Debt / EBITDA | -1.22 | -4.48 | -1.77 | -0.53 |
| Interest Coverage | -3.60 | -1.06 | -0.77 | -12.79 |
| Efficiency | ||||
| Inventory Turnover | 5.86 | 2.08 | 2.25 | 14.20 |
| Cash Conversion Cycle | -90.17 | 96.18 | 28.70 | -95.69 |